Processing

Please wait...

Settings

Settings

Goto Application

1. WO2013153458 - METHOD FOR THE PROGNOSIS AND TREATMENT OF CANCER METASTASIS

Publication Number WO/2013/153458
Publication Date 17.10.2013
International Application No. PCT/IB2013/001204
International Filing Date 15.03.2013
Chapter 2 Demand Filed 17.03.2014
IPC
G01N 33/574 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
C12Q 1/68 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
CPC
A61P 19/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
A61P 19/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
08for bone diseases, e.g. rachitism, Paget's disease
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
04specific for metastasis
A61P 43/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
C07K 16/2875
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2875against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
Applicants
  • FUNDACIO PRIVADA INSTITUT DE RECERCA BIOMEDICA [ES]/[ES]
  • INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS [ES]/[ES]
Inventors
  • ARNAL, Anna
  • TARRAGONA, Maria
  • PAVLOVIC, Milica
  • PLANET, Evarist
  • GOMIS, Roger
Priority Data
12382139909.04.2012EP
61/621,94909.04.2012US
61/724,80709.11.2012US
61/732,17530.11.2012US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) METHOD FOR THE PROGNOSIS AND TREATMENT OF CANCER METASTASIS
(FR) MÉTHODE DE PRONOSTIC ET DE TRAITEMENT DE MÉTASTASES CANCÉREUSES
Abstract
(EN) The present invention relates to a method for the prognosis of bone metastasis in triple negative (including basal-like) breast cancer or, alternatively, ER+ breast cancer (including luminal A and β) which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of triple negative (including basal-like) breast cancer metastasis or, alternatively, ER+ breast cancer (including luminal A and B) metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis. Finally, the invention relates to a method for typing of a subject suffering breast cancer and for classifying a subject from breast cancer into a cohort.
(FR) La présente invention concerne une méthode de pronostic de métastases osseuses dans un cancer du sein triple négatif (y compris celles de type basal) ou sinon, un cancer du sein ER+ (y compris ceux de type luminal A et B) qui comprend l'étape consistant à déterminer si le gène c-MAF est amplifié dans un échantillon de tumeur primaire. De même, l'invention concerne également une méthode de détermination de la tendance à développer des métastases osseuses par rapport à des métastases dans d'autres organes, qui comprend l'étape consistant à déterminer le niveau d'expression, l'amplification ou la translocation du gène c-MAF. L'invention concerne également une méthode de prédiction de métastases osseuses précoces chez un sujet atteint d'un cancer du sein. L'invention concerne également un inhibiteur de c-MAF comme agent thérapeutique destiné à être utilisé dans le traitement de métastases d'un cancer du sein triple négatif (y compris celles de type basal) ou sinon, de métastases d'un cancer du sein ER+ (y compris celles de type luminal A et B). L'invention concerne des kits de prédiction de métastases osseuses et de prédiction de l'issue clinique d'un sujet atteint de métastases osseuses. Pour finir, l'invention concerne une méthode de typage d'un sujet atteint d'un cancer du sein et de classification d'un sujet atteint d'un cancer du sein au sein d'une cohorte.
Latest bibliographic data on file with the International Bureau